Chengdu Aobang Pharmaceutical Co., Ltd

Phase I of the study: Primary objective: Using placebo as a control, evaluate the efficacy of brivaracetam tablets as an adjunctive treatment for 12 weeks in patients with partial seizures that are not controlled by 1-3 anti-epileptic drugs at a stable dose. Secondary objective: Using placebo as a control, evaluate the safety of brivaracetam tablets as an adjunctive treatment for 12 weeks in patients with partial seizures that are not controlled by 1-3 anti-epileptic drugs at a stable dose. Phase II of the study (open-label extension study): Primary objective: Evaluate the safety of brivaracetam tablets in the long-term treatment of patients with partial seizures that are not controlled by 1-3 anti-epileptic drugs at a stable dose. Secondary objective: Evaluate the efficacy of brivaracetam tablets in the long-term treatment of patients with partial seizures that are not controlled by 1-3 anti-epileptic drugs at a stable dose.

Main study objectives: To investigate the pharmacokinetic characteristics of the test preparation Telmisartan Amlodipine Tablets (Specifications: 80 mg/5 mg, produced by Chengdu Aobang Pharmaceutical Co., Ltd.) and the reference preparation Telmisartan Amlodipine Tablets (Twynsta®, Specifications: 80 mg/5 mg, licensed by Boehringer Ingelheim International GmbH) in healthy adult Chinese subjects after a single oral administration (fasting/postprandial), and to evaluate the bioequivalence of the two preparations in fasting and postprandial states, respectively, to provide a reference for the application and clinical use of the drug. Secondary study objectives: To evaluate the safety of the test preparation and the reference preparation in healthy adult Chinese subjects after a single oral administration (fasting/postprandial).

Primary objective: To observe the in vivo kinetics of nebivolol hydrochloride tablets after a single oral administration in healthy Chinese subjects, estimate the corresponding pharmacokinetic parameters, and conduct bioequivalence evaluation using nebivolol hydrochloride tablets (Nebilet®) certified by Menarini International Operations Luxembourg S.A. as the reference preparation. Secondary objective: To observe the safety of the test preparation of nebivolol hydrochloride tablets and the reference preparation of nebivolol hydrochloride tablets (Nebilet®) in healthy humans.